NCT04988932 is a NA clinical trial of Inhaled nitric oxide in SAH, sponsored by Insel Gruppe AG, University Hospital Bern.

Who is sponsoring NCT04988932?

NCT04988932 is sponsored by Insel Gruppe AG, University Hospital Bern.

What drugs are being tested in NCT04988932?

Interventions in NCT04988932: Inhaled nitric oxide.

What condition does NCT04988932 study?

NCT04988932 studies SAH, Inhaled Nitric Oxide, Cerebral Ischemia, Vasospasm.

Is NCT04988932 still recruiting?

NCT04988932 is currently completed. Last updated 4 August 2021.

Last reviewed 2021-08-04 · How we verify

NCT04988932

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Inhaled Nitric Oxide Treatment for Aneurysmal SAH Patients With Intractable Cerebral Vasospasm

Completed NA Last updated 4 August 2021

What this trial tests

NA trial testing Inhaled nitric oxide in SAH in 7 participants. Completed in 20 March 2020.

Timeline

31 July 2012

Primary endpoint
28 July 2019

20 March 2020

Quick facts

Lead sponsor	Insel Gruppe AG, University Hospital Bern
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	7
Start date	31 July 2012
Primary completion	28 July 2019
Estimated completion	20 March 2020
Sites	1 location across Switzerland

Drugs / interventions tested

Inhaled nitric oxide — full drug profile →

Conditions studied

SAH — all drugs for SAH →
Inhaled Nitric Oxide — all drugs for Inhaled Nitric Oxide →
Cerebral Ischemia — all drugs for Cerebral Ischemia →
Vasospasm — all drugs for Vasospasm →

Sponsor

Insel Gruppe AG, University Hospital Bern

Who can join

Adults 18 to 80, any sex, with SAH or Inhaled Nitric Oxide. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Aneurysmal subarachnoid haemorrhage (aSAH) is a rare but severe subtype of stroke with high mortality and morbidity. Besides rebleeding, delayed cerebral ischaemia and cerebral vasospasm (CVS) are thought to be major reasons for the poor outcome in survivors of aSAH. Despite advances in the detection and treatment of CVS 20-40% of CVS patients experience cerebral Ischaemia. Experimental animal studies for ischaemic stroke, traumatic brain injury, and SAH showed that inhaled nitric oxide (iNO) selectively dilates cerebral arteries and arterioles in hypoperfused brain tissue. The investigators therefore performed this prospective pilot study to evaluate the effects of iNO on cerebral perfusion in patients with refractory vasospasm after aSAH.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Nitric oxide: Clinical applications in critically ill patients.
Redaelli S, Magliocca A, Malhotra R, Ristagno G, et al · · 2022 · cited 28× · PMID 35123061 · DOI 10.1016/j.niox.2022.01.007
Therapeutic potential of nitric oxide and its donors in hemorrhagic and ischemic stroke: a systematic review.
Wang S, Wan S, Zhang X, Sun M, et al · · 2026 · PMID 41496301 · DOI 10.4103/mgr.medgasres-d-25-00161

Verify or expand the search:

Other trials of Inhaled nitric oxide

Trials testing the same drug.

NCT04224103 — Nitric Oxide in Venoarterial Extracorporeal Membrane Oxygenation (VA ECMO) · unknown
NCT03873298 — Inhaled NO in IPF and COPD During 6 Minute Walk Test · Phase 2 · unknown

Other recruiting trials for SAH

Currently open trials in the same condition.

NCT03754725 — Ferritin and Iron Burden in SAH sIRB · Phase 1, PHASE2 · recruiting

Other Insel Gruppe AG, University Hospital Bern trials

Trials by the same sponsor.

NCT06546384 — GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease · NA · not yet recruiting
NCT07524049 — Giving Children a Voice in Paediatric Anaesthesia · not yet recruiting
NCT07415668 — Motor Eloquent Navigated Transcranial Magnetic Stimulation for Radiosurgery Planning · NA · not yet recruiting
NCT07478536 — Stockholm3 Test Validation in Men on Active Surveillance in Switzerland (CHAS3 Trial) · not yet recruiting
NCT07201506 — Real-Time Intracardiac Echocardiography for Ventricular Arrhythmia Ablation · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04988932 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Insel Gruppe AG, University Hospital Bern
Last refreshed: 4 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04988932.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing